identified ADAR1, an enzyme that plays a role in the adenosine-to-inosine RNA editing process, as a predictive biomarker for remnant liver recurrence in patients with liver metastases stemming from CRC who are undergoing hepatic metastasectomy (288). Here, ADAR is linked to colorectal carcinoma.